Combining UCLA’s expertise in gut microbiome and immunology research, the Microbiome Vaccine Program (MVP) was established this year to create targeted treatments that modulate the gut microbiome in a way that boosts the immune system and keeps cancer-promoting gut bacteria at bay.
The MPV is a joint initiative of the California Institute for Immunology and Immunotherapy and the UCLA Goodman-Luskin Microbiome Center, led by integrative biology and physiology professor Elaine Hsiao.
We’re excited to be a part of this interdisciplinary collaboration that will train the next generation of scientists and accelerate the development of microbiome-based treatments to reduce the burden of gastrointestinal cancers.
Read more about the program’s research, goals and strengths, in this UCLA Health article.